Table 4. Whether Routine Screening for Genetic Biomarkers was Recommended by Therapeutic Area.

Counts represent instances wherein guidance sources recommended genetic screening in all patients being prescribed the applicable medication. CPIC guidelines were not included since they do not address whether genetic testing should be ordered.

Therapeutic Area	Recommendation for Routine Screening
	Overall	FDA	CPG
Oncology	137 (64.0%)	60 (50.4%)	77 (81.1%)
Hematology	35 (46.1%)	17 (38.6%)	18 (56.3%)
Psychiatry	2 (4.3%)	2 (5.4%)	0 (0%)
Cardiovascular	0 (0%)	0 (0%)	0 (0%)
Anesthetics	0 (0%)	0 (0%)	0 (0%)
Neurology	8 (28.6%)	8 (30.8%)	0 (0%)
Antivirals	3 (15.0%)	1 (6.3%)	2 (50.0%)
Anti-Infectives	4 (23.5%)	2 (14.3%)	2 (66.7%)
Gastroenterology	3 (17.6%)	3 (17.6%)	N/A
All Other TAs	14 (23.3%)	9 (16.4%)	5 (100%)
Total	206 (38.2%)	102 (27.8%)	104 (60.5%)

All data are presented as follows: counts (percentages). “All Other TAs” include pulmonary, rheumatology, endocrinology, analgesic, urology, immunosuppressant, medical countermeasure, metabolism, reproduction, addiction, and bone products.

Abbreviations: CPG = Clinical Practice Guidelines from U.S. Professional Organizations; CPIC = Clinical Pharmacogenetics Implementation Consortium; FDA = U.S. Food and Drug Administration; N/A = not applicable, indicates that no recommendations were provided by the designated source